Navigation Links
Neural stem cell transplants for spinal cord injury maximized by combined, complimentary therapies
Date:4/17/2012

Tampa, Fla. (April. 17, 2012) Combined, complimentary therapies have the ability to maximize the benefits of neural stem cell (NSC) transplantation for spinal cord repair in rat models, according to a study carried out by a team of Korean researchers who published in a recent issue of Cell Transplantation (20:9), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

"When transplanted, neural stem cells have demonstrated their therapeutic potential to reverse complex pathological processes following spinal cord injury," said study corresponding author Dr. Byung G. Kim of the Ajou University School of Medicine's Brain Disease Research Center and Department of Neurology, Republic of Korea. "However, many obstacles cannot be overcome by NSC transplant alone."

Their study demonstrated that a combination of treatment strategies - a polymer scaffold, neurotrophin-3 (NT3) and chondroitinase (an enzyme which helps digest the glial scar that formed after a spinal cord injury) - provided added therapeutic benefits to NSC transplantation. The implantation of a polymer scaffold designed to bridge lesion cavities, created a favorable tissue environment for nerve growth. Incorporating the NT3 gene into the transplanted cells improved cell survival and migration while the addition of chondroitinase positively affected neural activity between the scaffold and the spinal cord.

"The poly (ε-caprolactone) [PCL] scaffold in our study appeared to function like a reservoir supplying migratory NSCs to the spinal cord," said Dr. Kim. "The NSCs grafted with the scaffolds survived the transplantation and migrated to the host spinal cord."

The study included four animal groups, only one of which received the full combination of therapies. Rats in the full combination therapy group were found to have some restored neuroplasticity and enhanced remyelation of contralateral white matter. All four groups subsequently underwent functional testing for locomotor recovery.

"Rats in the full combination group attained well-coordinated plantar stepping accompanied by improved ankle positioning and toe clearance and reduced paw placement errors," explained Dr. Kim. "Furthermore, animals with the full complement of combination strategies responded to transcranial magnetic stimulation."

The researchers concluded that, given their success, similar treatment for humans should be carried out in a chronic injury setting.

"We believe that our results have important clinical implications regarding the future design of NSC-based therapeutic strategies for human victims of traumatic spinal cord injury," concluded Dr. Kim and co-authors.

"The use of multiple strategies to treat spinal cord injury, could prove to be more effective than any single treatment." Cell Transplantation section editor Dr. John Sladek, professor of neurology and pediatrics at the University of Colorado School of Medicine. "Changing the hostile environment post spinal cord injury by the use of scaffolds, neurotrophins and breakdown of the glial scar creates a favorable milieu for NSCs to be able to exert benefit".


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Neural mechanisms of value bias in the human visual cortex
2. Obesity starts in the head? 6 newly discovered genes for obesity have a neural effect
3. I feel your pain: Neural mechanisms of empathy
4. Neural mapping paints a haphazard picture of odor receptors
5. Ex vivo neural stem cell expansion
6. Low levels of vitamin B12 may increase risk for neural tube defects
7. Early brain activity sheds new light on the neural basis of reading
8. Creating ideal neural cells for clinical use
9. Identification of a key molecular pathway required for brain neural circuit formation
10. Neural stem cell differentiation factor discovered
11. Essential nutrient found in eggs may help lower risk of neural tube defects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the ... their offering. The report forecasts the global military biometrics ... The report has been prepared based on an in-depth ... landscape and its growth prospects over the coming years. The report also ...
(Date:12/15/2016)... LONDON , Dec. 14, 2016 "Increase ... mobile biometrics market" The mobile biometrics market is expected ... USD 49.33 billion by 2022, at a CAGR of ... by factors such as the growing demand for smart ... mobile transactions. "Software component is expected to ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today ... based Phase 1 trial with severe kidney ... reducing inflamed protein biomarkers in patients with severe kidney ... this is the first time in medical history that ... between epigenetic regulation and its potential for positive disease ...
(Date:1/23/2017)... ... January 23, 2017 , ... Calvert Labs, Inc. announced ... and Senior Director, Safety Pharmacology. Dr. Thomas earned his M.Sc. and Ph.D. ... career as an academic and industry preclinical drug developer spans more than three ...
Breaking Biology Technology: